The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

The Federal Trade Commission on Tuesday released an interim report saying that powerful drug middlemen marked up drugs for ...

The U.S. Federal Trade Commission on Tuesday published the second part of its investigation into how prescription drug ...

The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...

Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue. • The Federal Trade Commission (FTC) released a report showing that pharmacy benefit managers (PBMs) ...

The Federal Trade Commission suggests that PBMs profit from specialty generic drugs such as those for cancer and HIV and ...

2025 promises to be a tumultuous year for the American healthcare and pharma sector. Increased scrutiny on pricing and the ...

Following a rough fourth quarter, we see the healthcare sector overall as undervalued, with a median discount to our fair ...

The Federal Trade Commission has published a report that found pharmacy benefit managers Caremark Rx LLC (CVS), Express Scripts and OptumRx marked up numerous specialty generic drugs by ...

The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs ...

Pharmacy benefit managers "are raking in billions in excess revenue—$7.3 billion over just five years—while squeezing ...